Unicycive Therapeutics, Inc.
UNCY · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | -29% | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | 100% | 100% | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -4,470.8% | -1,881.3% | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -4,525% | -1,898.8% | – |
| EPS Diluted | -5.6 | -1.28 | -1.2 | -8.6 |
| % Growth | -337.5% | -6.7% | 86% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |